Cardiorespiratory Fitness and Risk of COVID-19 Infection, Mortality

Pavankumar Kamat

Disclosures

May 18, 2021

Takeaway

  • Estimated cardiorespiratory fitness (eCRF) had no significant association with the risk of testing positive for COVID-19.

  • However, people with moderate or higher eCRF had a significantly lower risk of dying from COVID-19.

Why this matters

  • Physical activity is a modifiable behaviour that positively affects CRF and an effective intervention to reduce the negative health effects of COVID-19 lockdowns.

  • The findings provide additional support to these recommendations and suggest that prior physical activity may offer protection against dying from COVID-19.

Study design

  • A prospective cohort study of 2690 participants from the UK Biobank who were tested for COVID-19.

  • CRF was estimated using maximum oxygen consumption (VO2 max) and classified as low (<20th percentile), moderate (20th to <80th percentile) and high (≥80th percentile) within sex and 10-year age groups.

  • Funding: None.

Key results

  • Of 2690 participants, 346 tested positive for COVID-19.

  • No difference was seen in the mean estimated VO2 max between those who were tested for COVID-19 (27.3±5.5 mL/kg/min) and those who tested positive for COVID-19 (27.3±5.4 mL/kg/min).

  • Moderate (adjusted risk ratio [aRR], 0.93; 95% CI, 0.72-1.21) and high eCRF (aRR, 0.77; 95% CI, 0.52-1.15) vs low eCRF were not associated with an increased risk of testing positive for COVID-19.

  • Conversely, low eCRF vs moderate and high eCRF was associated with >2 times higher risk of dying from COVID-19 (aRR, 2.34; 95% CI, 1.35-4.05).

  • Compared with low eCRF, the risk of dying from COVID-19 increased with (aRR; 95% CI):

    • moderate eCRF (0.43; 0.25-0.75); and

    • high eCRF (0.37; 0.16-0.85).

Limitations

  • Approximate 10-year lag between baseline measurements and COVID-19 testing.

 

Christensen RAG, Arneja J, St Cyr K, Sturrock SL, Brooks JD. The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study. PLoS One. 2021;16(5):e0250508. doi: 10.1371/journal.pone.0250508. PMID: 33951071.  View full text

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....